UK healthtech startup Lucida Medical has closed an £8.7 million funding round led by IW Capital, with participation from XTX Ventures and Macmillan Cancer Support, to accelerate its AI-powered cancer diagnostics platform. The investment comes as the company looks to expand beyond prostate cancer and bring same-day diagnostic capabilities to a wider range of cancer types.
Lucida’s AI system, already deployed in the NHS, analyses MRI scans to deliver risk scores in minutes, aiming to reduce delays, unnecessary biopsies and treatment backlogs.
Tackling a Critical Bottleneck in Cancer Care
Prostate cancer is one of the most common cancers among men in the UK, with around 610,000 men living with the disease and only 55% diagnosed before the cancer spreads. Radiology shortages are compounding the problem, with a projected 40% shortfall in UK radiologists by 2028.
Lucida’s AI addresses this bottleneck by rapidly analysing scans and flagging high-risk cases for priority review by clinicians. The goal is faster, more confident decision-making and ultimately earlier treatment for patients.
Dr. Antony Rix, Co-founder and CEO of Lucida Medical, says: “Cancer imaging volumes are rising rapidly but reporting capacity is not keeping pace. Our goal is to give clinicians faster, more confident decisions while reducing unnecessary interventions for patients.”
More from Funding
- Deaku Raises £480K To Build “Missing Infrastructure” For The Creator Economy
- Silverflow Raises $40 Million Series B As Cloud-Native Payments Platform Scales Globally
- Plurio By Elly Analytics Raises $3.5M To Automate Up To 90% Of Performance Marketers’ Daily Work
- Smart Bricks raises $5M led by Andreessen Horowitz (a16z) to Build the AI Infrastructure Layer for Global Real Estate
- Stacks Raises $23M Series A To Automate Enterprise Finance With Agentic AI
- Maternal Health AI Startup, Matresa, Secures £315,000 In Pre-Seed Funding In An Effort To Combat UK Crisis
- Elaia’s Fifth Digital Venture Fund (DV5) Announces First Close At €120m To back The Best Of European Tech
- Deep Space Energy Closes €930K Pre-Seed Round, To Generate Electricity On The Moon
AI Is Driving Diagnoses That Are Faster and More Accurate
Lucida’s first AI product focuses on prostate cancer but the company plans to expand across other cancer types. Its platform, Pi™ (Prostate Intelligence), has been trained and validated on thousands of patient scans and is CE-certified for use in the UK and EU.
Already, the technology is deployed in 15 NHS hospitals, with Somerset NHS Foundation Trust reporting improved triage and reduced waiting times. If the AI flags a scan as high-risk, it triggers urgent review and rapid biopsy scheduling, potentially shaving weeks off traditional diagnostic pathways.
This Funding Fuels Growth and Expansion
The £8.7 million investment will support Lucida’s continued growth, including pursuit of US FDA approval and the expansion of its AI diagnostics platform beyond prostate cancer.
David Fisher, Senior Investment Director at IW Capital, highlights the opportunity: “Lucida Medical is addressing a critical bottleneck in modern healthcare. The company combines deep clinical expertise, strong NHS validation, and a scalable technology platform, and we are pleased to support its next phase of growth.”
For fintech-style investors and healthtech watchers, Lucida represents a case study in AI solving real-world operational challenges in high-stakes industries, where efficiency and accuracy are non-negotiable.
Partnerships and Impact
Macmillan Cancer Support, which also participated in the round, emphasises the human impact: “We need faster diagnosis alongside better awareness so men seek help earlier. Lucida Medical’s AI platform has the potential to make a very real and immediate improvement for people living with cancer,” says Anthony Cunliffe, Lead Medical Advisor.
XTX Ventures brings expertise in machine learning and operational support, helping Lucida scale effectively while maintaining clinical accuracy.
As AI adoption grows across healthcare, Lucida Medical’s approach illustrates the intersection of deep learning and clinical practice. The startup is part of a broader trend where AI is no longer experimental but operational, supporting hospitals, doctors and patients in real time.
With rising cancer rates, radiologist shortages and increasing pressure on health systems, this funding could mark a turning point. That is, transforming not just prostate cancer diagnosis but potentially the wider landscape of oncology diagnostics in the UK and beyond.
